IBI343 plus chemo for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that cannot be removed with surgery.
- Your cancer has gotten worse or you couldn't tolerate standard chemo with gemcitabine.
- You are at least 18 years old and in reasonably good health (able to do daily activities).
- Your tumor tests positive for a protein called CLDN18.2.
- You have not had certain other treatments or medical conditions that would make this trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
This trial tests whether adding the drug IBI343 to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. It is for those whose tumors have a specific protein called CLDN18.2 and have not spread to other parts of the body.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.